SCHEMBL573658

SCHEMBL573658

COCc1cc(N2CCC(N(C)C)CC2)ccc1Nc1ncc(C)c(-c2c[nH]c3ccccc23)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.61
ALK Q9UM73 4/20 0.58
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
JUN P05412 1/20 0.45
MAPK8 P45983 1/20 0.45
MAPK9 P45984 1/20 0.45
MAPK10 P53779 1/20 0.45
IGF1R P08069 2/20 0.44
AURKA O14965 1/20 0.44
INSR P06213 1/20 0.44
ROS1 P08922 1/20 0.44
EML4 Q9HC35 1/20 0.44
CCNT1 O60563 3/20 0.44
CCNK O75909 3/20 0.44
CDK7 P50613 3/20 0.44
CDK9 P50750 3/20 0.44
CCNH P51946 3/20 0.44
CDK12 Q9NYV4 3/20 0.44
MNAT1 P51948 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL517613 0.89 EGFR (0.75) EGFRALKJAK2JAK1IGF1R
SCHEMBL518394 0.83 ALK (0.83) EGFRALKIGF1RAURKAINSR
SCHEMBL518242 0.82 EGFR (0.60) EGFRALKJAK2JAK1JUN
SCHEMBL573659 0.82 EGFR (0.57) EGFRALKJAK2JAK1JUN
SCHEMBL517036 0.81 EGFR (0.74) EGFRALKIGF1RAURKAINSR
SCHEMBL517390 0.80 ALK (0.84) EGFRALKJAK2JAK1IGF1R
SCHEMBL517301 0.80 EGFR (0.72) EGFRALKIGF1RAURKAINSR
SCHEMBL517332 0.79 ALK (0.70) EGFRALKJAK2JAK1JUN
SCHEMBL517586 0.77 ALK (0.65) EGFRALKIGF1RCCNT1CCNK
SCHEMBL517495 0.77 EGFR (0.85) EGFRALKIGF1RINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601186-A2 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS AstraZeneca AB (SE) 2013-06-12 EP disclosed
WO-2012017239-A2 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-09 WO disclosed